Evidence map›Paper›PMID 27977772›Full record

ArticlePloS one2016

Inhibition of cAMP-Dependent PKA Activates β2-Adrenergic Receptor Stimulation of Cytosolic Phospholipase A2 via Raf-1/MEK/ERK and IP3-Dependent Ca2+ Signaling in Atrial Myocytes.

M R Pabbidi, X Ji, J T Maxwell, G A Mignery, A M Samarel, S L Lipsius

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Activation of IPAmerican journal of physiology. Heart and circulatory physiology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

M R PabbidiDepartment of Pharmacology, University of Mississippi Medical Center, Jackson, MS, United States of America.ORCID http://orcid.org/0000-0001-6353-9570
X JiDepartment of Physiology, Loyola University Medical Center, Maywood, IL, United States of America.
J T MaxwellDepartment of Physiology, Loyola University Medical Center, Maywood, IL, United States of America.
G A MigneryDepartment of Physiology, Loyola University Medical Center, Maywood, IL, United States of America.
A M SamarelDepartment of Medicine, Loyola University Medical Center, Maywood, IL, United States of America.
S L LipsiusDepartment of Physiology, Loyola University Medical Center, Maywood, IL, United States of America.
Loyola University Medical Center · USJackson Memorial Hospital · US

Funding

Sarcomeric Modifications and Progressive Cardiac MaladaptationP01HL062426 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DE TOMBE, PIETER P. · 2000 to 2020
$42.4M
Beta-Adrenergic Receptor Function in Atrial MyocytesR01HL079038 · NHLBI · LOYOLA UNIVERSITY CHICAGO · PI LIPSIUS, STEPHEN LLOYD · 2005 to 2008
$1.4M
NHLBI NIH HHS P01 HL062426NHLBI NIH HHS R01 HL079038
6 · The paper itself

Abstract

We previously reported in atrial myocytes that inhibition of cAMP-dependent protein kinase (PKA) by laminin (LMN)-integrin signaling activates β2-adrenergic receptor (β2-AR) stimulation of cytosolic phospholipase A2 (cPLA2). The present study sought to determine the signaling mechanisms by which inhibition of PKA activates β2-AR stimulation of cPLA2. We therefore determined the effects of zinterol (0.1 μM; zint-β2-AR) to stimulate ICa,L in atrial myocytes in the absence (+PKA) and presence (-PKA) of the PKA inhibitor (1 μM) KT5720 and compared these results with atrial myocytes attached to laminin (+LMN). Inhibition of Raf-1 (10 μM GW5074), phospholipase C (PLC; 0.5 μM edelfosine), PKC (4 μM chelerythrine) or IP3 receptor (IP3R) signaling (2 μM 2-APB) significantly inhibited zint-β2-AR stimulation of ICa,L in-PKA but not +PKA myocytes. Western blots showed that zint-β2-AR stimulation increased ERK1/2 phosphorylation in-PKA compared to +PKA myocytes. Adenoviral (Adv) expression of dominant negative (dn) -PKCα, dn-Raf-1 or an IP3 affinity trap, each inhibited zint-β2-AR stimulation of ICa,L in + LMN myocytes compared to control +LMN myocytes infected with Adv-βgal. In +LMN myocytes, zint-β2-AR stimulation of ICa,L was enhanced by adenoviral overexpression of wild-type cPLA2 and inhibited by double dn-cPLA2S505A/S515A mutant compared to control +LMN myocytes infected with Adv-βgal. In-PKA myocytes depletion of intracellular Ca2+ stores by 5 μM thapsigargin failed to inhibit zint-β2-AR stimulation of ICa,L via cPLA2. However, disruption of caveolae formation by 10 mM methyl-β-cyclodextrin inhibited zint-β2-AR stimulation of ICa,L in-PKA myocytes significantly more than in +PKA myocytes. We conclude that inhibition of PKA removes inhibition of Raf-1 and thereby allows β2-AR stimulation to act via PKCα/Raf-1/MEK/ERK1/2 and IP3-mediated Ca2+ signaling to stimulate cPLA2 signaling within caveolae. These findings may be relevant to the remodeling of β-AR signaling in failing and/or aging heart, both of which exhibit decreases in adenylate cyclase activity.

Indexed as

AnimalsCalcium SignalingCarbazolesCatsCells, CulturedCyclic AMP-Dependent Protein KinasesExtracellular Signal-Regulated MAP KinasesFemaleGroup IV Phospholipases A2Heart AtriaInositol 1,4,5-Trisphosphate ReceptorsMaleMitogen-Activated Protein Kinase KinasesMyocytes, CardiacProto-Oncogene Proteins c-rafPyrrolesCarbazolesCyclic AMP-Dependent Protein KinasesExtracellular Signal-Regulated MAP KinasesGroup IV Phospholipases A2Inositol 1,4,5-Trisphosphate ReceptorsKT 5720Mitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins c-rafPyrrolesReceptors, Adrenergic, beta-2

Identifiers

PMID27977772
PMCPMC5158063
OpenAlexW2561683901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.